|Partial Close, 6/2009 ||$500k|
|Venture Round, 2/2011 ||$1.7M|
|Venture Round, 9/2011 |
Draper Fisher Jurvetson (DFJ)
|Private Equity, 4/2013 |
|Debt, 5/2012 ||$395k|
Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.